United Health Products Provides Corporate Update
MWN-AI** Summary
United Health Products, Inc. (OTCQB: UEEC) announced a corporate update on December 15, 2025, regarding its ongoing discussions with the Food & Drug Administration (FDA) to address a Warning Letter issued on March 25, 2025. The letter highlighted specific violations of clinical procedures during UHP’s 2019 clinical trial. In response, the company submitted a corrective action on April 14, 2025, and underwent a post-audit validation of relevant clinical data. On December 10, the FDA evaluated UHP's corrective measures, requesting additional information and making comments on UHP’s plans to initiate another clinical study. UHP disputes some of the FDA's findings and has a conference scheduled before year-end to seek resolution, which it believes could allow the company to start a new study in early 2026.
In addition to these discussions, UHP completed two long-term pre-clinical studies necessary for its Premarket Approval (PMA) resubmission. One study assessed the absorption rates and tissue reactivity of UHP's CelluSTAT Hemostatic Gauze compared to standard care products. Results indicated that CelluSTAT showed no signs of material at implantation sites after two weeks and exhibited no tissue reactivity, unlike the standard which remained for over eight weeks and demonstrated signs of inflammation. These findings reinforce the advantages of UHP's product, potentially reducing post-surgical risks.
Looking ahead, UHP plans to organize a study aimed at expanding the use of CelluSTAT in various laparoscopic procedures, aligning with increasing surgical trends in the U.S. The outcomes will support a supplemental FDA PMA application. For more information about UHP and its products, visit www.uhpcorp.com.
MWN-AI** Analysis
United Health Products, Inc. (OTCQB: UEEC) is currently navigating a pivotal phase in its operations as it addresses a Warning Letter from the FDA regarding clinical procedure violations identified during its 2019 clinical trial. The company has expressed confidence about resolving these findings, aiming to commence a new clinical study by early 2026. This pivotal dialogue with the FDA, alongside the completion of two long-term preclinical studies on its CelluSTAT Hemostatic Gauze, positions UHP as a potentially significant player in the surgical market.
The positive preclinical results showcasing that CelluSTAT demonstrates a favorable safety profile compared to existing standard care options are particularly noteworthy. The gauze's rapid absorption and lack of adverse tissue reactions could offer a competitive edge, especially as minimally invasive laparoscopic procedures grow in popularity. UHP’s anticipated supplemental FDA PMA application could further enhance its market prospects, provided it successfully expands the indications for use.
Investors should closely monitor the outcomes of UHP’s upcoming FDA conference and planned studies. Securing FDA approval for human surgical applications will be crucial not only for the company’s product viability but also for its stock valuation. Potential investors might consider this a speculative opportunity as the company’s market cap seems modest given the clinical potential of its innovations.
However, market participants should remain aware of the inherent risks associated with biotech investing, especially in companies that face regulatory scrutiny. Continued communication from UHP, especially regarding FDA responses and study results, will be essential in shaping market sentiment moving forward. Careful observation of these developments could provide insights into the company’s future performance and growth potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MT. LAUREL, NJ - December 15, 2025 (NEWMEDIAWIRE) - United Health Products, Inc. (OTCQB: UEEC) today provided a status update on its discussions with the Food & Drug Administration (FDA) to resolve the Warning Letter issued on March 25, 2025, identifying certain violations of required clinical procedures that occurred during the company’s 2019 clinical trial.
On April 14, 2025, the company submitted a response to FDA that addressed the violations, followed by a post-audit and validation of certain clinical trial data. On December 10, FDA issued an evaluation of UHP’s response to the Warning Letter containing conclusions on UHP’s oversight of the 2019 study, requests for additional information and comments on the UHP’s plan to complete an additional clinical study. The company disputes certain of FDA’s findings and has scheduled a conference with FDA before yearend with the objective of discussing and resolving the disputed findings, which it believes will ultimately result in the ability to commence a new study early in 2026.
Company Update
UHP has also recently completed two long-term, pre-clinical studies that are required for its planned Premarket Approval resubmission. One of these studies compares the rates of absorption and tissue reactivity of UHP’s CelluSTAT Hemostic Gauze and the current “standard of care” product. In the study, investigators subcutaneously implanted gauze samples into animal models and monitored the implantation sites over several months. Among other positive findings the study showed no evidence of any CelluSTAT material two weeks post-implantation and no tissue reaction at any time. This is compared to standard of care gauze material, which remained present at the implantation site for over eight weeks and showed evidence of tissue reactivity (measured by the presence of macrophages and giant cells) at three months. These results confirm prior findings and suggest that use of UHP’s CelluSTAT Hemostatic Gauze carries less risk of post-surgical complications such as mass formation, imaging mimicry and chronic inflammation.
Looking ahead, the company is organizing a study to potentially expand the indications for use of CelluSTAT, assuming approval for use in human surgical procedures. UHP has scheduled an animal model study to examine and confirm the usability of CelluSTAT in a variety of the most common laparoscopic procedures, which represent a growing majority of surgeries in the U.S. market today. The results of this planned study will be submitted as part of a supplemental FDA PMA application.
About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market.
For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.
The company can also be reached by phone or text message at 475.755.1005.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
View the original release on www.newmediawire.com
FAQ**
What specific violations identified by the FDA does United Health Products Inc (UEEC) dispute regarding the 20clinical trial, and how might this impact their future studies?
How does the completion of the two long-term pre-clinical studies position United Health Products Inc (UEEC) for a successful Premarket Approval resubmission?
What potential implications could the results of the upcoming animal model study have for United Health Products Inc (UEEC) in expanding the indications for use of CelluSTAT in laparoscopic procedures?
Given the safety and efficacy findings regarding CelluSTAT compared to standard of care products, how might this influence the FDA’s evaluation of United Health Products Inc (UEEC) during the approval process?
**MWN-AI FAQ is based on asking OpenAI questions about United Health Products Inc (OTC: UEEC).
NASDAQ: UEEC
UEEC Trading
-5.35% G/L:
$0.0601 Last:
29,370 Volume:
$0.06 Open:
